[HTML][HTML] Optimal management of heart failure and chronic obstructive pulmonary disease: Clinical challenges

JJ Cuthbert, P Pellicori, AL Clark - International Journal of General …, 2022 - ncbi.nlm.nih.gov
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are common causes
of breathlessness which frequently co-exist; one potentially exacerbating the other …

Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk

PMA Calverley, JA Anderson, RD Brook… - American Journal of …, 2018 - atsjournals.org
Rationale: Many patients with chronic obstructive pulmonary disease (COPD) have an
accelerated loss of lung function. It is unclear whether drug treatment can modify this in …

Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities

LY Lee, GSY Hew, M Mehta, SD Shukla, S Satija… - Life sciences, 2021 - Elsevier
Eosinophils are bi-lobed, multi-functional innate immune cells with diverse cell surface
receptors that regulate local immune and inflammatory responses. Several inflammatory and …

Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease

B Guerra, SR Haile, B Lamprecht, AS Ramírez… - BMC medicine, 2018 - Springer
Background External validations and comparisons of prognostic models or scores are a
prerequisite for their use in routine clinical care but are lacking in most medical fields …

Early Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease: The Costs and Benefits of Case Finding

SD Aaron, M Montes de Oca, B Celli… - American Journal of …, 2024 - atsjournals.org
In 2020, the prevalence of clinician-diagnosed chronic obstructive pulmonary disease
(COPD) among US adults aged> 18 years was 5.6%(95% confidence interval [CI], 5.2 …

Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases

M Cazzola, L Calzetta, B Rinaldi, C Page, G Rosano… - Drugs, 2017 - Springer
Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases often coexist.
The mechanistic links between these two diseases are complex, multifactorial and not …

Smoking cessation/vaccinations

MM de Oca - Clinics in chest medicine, 2020 - chestmed.theclinics.com
Cigarette smoking is the leading risk factor for chronic obstructive pulmonary disease
(COPD) in developed countries and an important contributor to the burden in most societies …

Generalizability of risk stratification algorithms for exacerbations in COPD

JK Ho, A Safari, A Adibi, DD Sin, K Johnson… - Chest, 2023 - Elsevier
Background Contemporary management of COPD relies on exacerbation history to risk-
stratify patients for future exacerbations. Multivariable prediction models can improve the …

Simplifying pharmacotherapy for patients with COPD: a viewpoint

B Celli, J Vestbo - European Respiratory Journal, 2023 - Eur Respiratory Soc
Tweetable abstract Review of simple clinical and physiological data can help stratify COPD
severity and guide the pharmacotherapy most likely to improve patient outcomes …

Urinary incontinence in chronic obstructive pulmonary disease: a common co-morbidity or a typical adverse effect?

S Battaglia, A Benfante, S Principe, L Basile… - Drugs & aging, 2019 - Springer
Urinary incontinence (UI) is defined as a loss of bladder control and is characterized by the
complaint of any involuntary leakage of urine. Evidence suggests that the prevalence of UI is …